



September 12, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Correction Regarding New Drug Introduction Notice & Report Pursuant to 18 V.S.A. § 4637

To Whom It May Concern:

On August 15, 2019, and pursuant to 18 V.S.A. § 4637, Teva Pharmaceuticals USA, Inc. ("Teva") submitted a new drug introduction notice for the following two versions of doxycycline hyclate DR, which Teva had released to the commercial market the day before, on August 14, 2019:

- DOXYCYCLINE HYCLATE DR TABLET 50MG 120 (NDC 00591-4550-22), and
- DOXYCYCLINE HYCLATE DR TABLET 200MG 60 (NDC 00591-4575-60).

That notice, and the subsequent report that Teva submitted concerning the above, included a typographical error as concerns the 50MG version (NDC 00591-4550-22). In particular, WAC on the 50MG version (NDC 00591-4550-22) was incorrectly reported as being \$1,314.60 at launch. The correct figure is \$1,134.60.

We apologize for the mistake, and we thank you for your consideration.

Sincerely,

A handwritten signature in black ink, appearing to read "Brian Savage", written over a light blue horizontal line.

Brian Savage
General Counsel, US Generics
Teva Pharmaceuticals USA, Inc.